- Home
- POAI vs ACXP Comparison
POAI vs ACXP Comparison
Compare POAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- ACXP
- Stock Information
- Founded
- POAI 2002
- ACXP 2017
- Country
- POAI United States
- ACXP United States
- Employees
- POAI N/A
- ACXP N/A
- Industry
- POAI Industrial Specialties
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- ACXP Health Care
- Exchange
- POAI Nasdaq
- ACXP Nasdaq
- Market Cap
- POAI 8.9M
- ACXP 8.4M
- IPO Year
- POAI N/A
- ACXP 2021
- Fundamental
- Price
- POAI $0.80
- ACXP $0.54
- Analyst Decision
- POAI Hold
- ACXP Strong Buy
- Analyst Count
- POAI 1
- ACXP 2
- Target Price
- POAI N/A
- ACXP $10.00
- AVG Volume (30 Days)
- POAI 164.4K
- ACXP 18.6M
- Earning Date
- POAI 08-12-2025
- ACXP 08-08-2025
- Dividend Yield
- POAI N/A
- ACXP N/A
- EPS Growth
- POAI N/A
- ACXP N/A
- EPS
- POAI N/A
- ACXP N/A
- Revenue
- POAI $1,729,269.00
- ACXP N/A
- Revenue This Year
- POAI $486.27
- ACXP N/A
- Revenue Next Year
- POAI $65.50
- ACXP N/A
- P/E Ratio
- POAI N/A
- ACXP N/A
- Revenue Growth
- POAI 24.17
- ACXP N/A
- 52 Week Low
- POAI $0.55
- ACXP $0.30
- 52 Week High
- POAI $3.06
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- POAI 32.97
- ACXP 52.07
- Support Level
- POAI $0.73
- ACXP $0.45
- Resistance Level
- POAI $0.86
- ACXP $0.52
- Average True Range (ATR)
- POAI 0.05
- ACXP 0.08
- MACD
- POAI -0.00
- ACXP -0.01
- Stochastic Oscillator
- POAI 30.59
- ACXP 20.83
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.